- Home
- NRIM vs VALN Comparison
NRIM vs VALN Comparison
Compare NRIM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- VALN
- Stock Information
- Founded
- NRIM 1990
- VALN 2012
- Country
- NRIM United States
- VALN France
- Employees
- NRIM N/A
- VALN N/A
- Industry
- NRIM Savings Institutions
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRIM Finance
- VALN Health Care
- Exchange
- NRIM Nasdaq
- VALN Nasdaq
- Market Cap
- NRIM 514.9M
- VALN 542.5M
- IPO Year
- NRIM N/A
- VALN 2021
- Fundamental
- Price
- NRIM $96.27
- VALN $5.90
- Analyst Decision
- NRIM
- VALN Strong Buy
- Analyst Count
- NRIM 0
- VALN 3
- Target Price
- NRIM N/A
- VALN $15.33
- AVG Volume (30 Days)
- NRIM 69.1K
- VALN 11.9K
- Earning Date
- NRIM 07-23-2025
- VALN 08-12-2025
- Dividend Yield
- NRIM 2.63%
- VALN N/A
- EPS Growth
- NRIM 46.48
- VALN N/A
- EPS
- NRIM 7.52
- VALN N/A
- Revenue
- NRIM $164,695,000.00
- VALN $201,099,222.00
- Revenue This Year
- NRIM N/A
- VALN $18.74
- Revenue Next Year
- NRIM $7.05
- VALN $29.26
- P/E Ratio
- NRIM $12.95
- VALN N/A
- Revenue Growth
- NRIM 26.35
- VALN 21.64
- 52 Week Low
- NRIM $55.58
- VALN $3.62
- 52 Week High
- NRIM $100.21
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- NRIM 66.91
- VALN 48.62
- Support Level
- NRIM $97.35
- VALN $5.57
- Resistance Level
- NRIM $100.21
- VALN $6.08
- Average True Range (ATR)
- NRIM 2.20
- VALN 0.26
- MACD
- NRIM 0.53
- VALN 0.04
- Stochastic Oscillator
- NRIM 81.39
- VALN 61.12
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.